Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization

EMBO Molecular Medicine

Volumn 7, Issue 9, 2015, Pages 1229-1243

  Cannon, Megan V ^a   Silljé, Herman Hw ^a   Sijbesma, Jürgen Wa ^a   Vreeswijk Baudoin, Inge ^a   Ciapaite, Jolita ^a   van der Sluis, Bart ^a   van Deursen, Jan ^b   Silva, Gustavo Jj ^c   de Windt, Leon J ^c   Gustafsson, Jan Åke ^d,e   van der Harst, Pim ^a   van Gilst, Wiek H ^a   de Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d University of Houston   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glucose metabolism; Left ventricular hypertrophy; Liver X receptor; Nuclear receptor; O GlcNAcylation

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEXOSAMINE; LIVER X RECEPTOR ALPHA; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVIC ACID; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; GLUCOSE; LIVER X RECEPTOR; NR1H3 PROTEIN, MOUSE; ORPHAN NUCLEAR RECEPTOR;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; DEFICIENCY; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARDIOMEGALY; GENE EXPRESSION PROFILING; GLUCOSE; LIPID METABOLISM; LIVER X RECEPTORS; MICE, TRANSGENIC; MYOCARDIUM; ORPHAN NUCLEAR RECEPTORS;

EID: 84940750130     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404669     Document Type: Article

References (56)

1. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA (2001) Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 107: 565-573
2. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267: H742-H750
3. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U et al (2012) Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail 14: 120-129
4. Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, Tontonoz P (2011) Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 140: 1052-1062
5. Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435: 297-312
6. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34: 1424-1431
7. Chen M, Beaven S, Tontonoz P (2005) Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha. J Lipid Res 46: 2570-2579
8. Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI (2003) Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 278: 48283-48291
9. Darley-Usmar VM, Ball LE, Chatham JC (2012) Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol 52: 538-549
10. Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 113: 709-724
11. Domenighetti AA, Danes VR, Curl CL, Favaloro JM, Proietto J, Delbridge LM (2010) Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2 +) and proton flux dysregulation. J Mol Cell Cardiol 48: 663-672
12. Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79
13. Giannarelli C, Cimmino G, Connolly TM, Ibanez B, Ruiz JM, Alique M, Zafar MU, Fuster V, Feuerstein G, Badimon JJ (2012) Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J 33: 264-273
14. Griesel BA, Weems J, Russell RA, Abel ED, Humphries K, Olson AL (2010) Acute inhibition of fatty acid import inhibits GLUT4 transcription in adipose tissue, but not skeletal or cardiac muscle tissue, partly through liver X receptor (LXR) signaling. Diabetes 59: 800-807
15. Gulick J, Subramaniam A, Neumann J, Robbins J (1991) Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 266: 9180-9185
16. Hayek S, Nemer M (2011) Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther 29: 362-376
17. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111: 1399-1407
18. Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, Burris TP (2004) T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 83: 184-187
19. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9: 213-219
20. Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M (2005) Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 54: 1108-1115
21. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ (1995) Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377: 151-155
22. Kolwicz SC Jr, Tian R (2011) Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 90: 194-201
23. Kolwicz SC Jr, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 113: 603-616
24. Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der Harst P, Sillje HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, de Boer RA (2010) Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 12: 1042-1050
25. Kumar N, Solt LA, Conkright J, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Nuhant P, Burris T, Mercer BA et al (2010) Campaign to Identify Novel Modulators of the Retinoic Acid Receptor-Related Orphan Receptors (ROR). In Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US)
26. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL et al (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100: 5419-5424
27. Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P (2007) GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 151: 450-456
28. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R (2002) Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106: 2125-2131
29. Lu B, Yu H, Zwartbol M, Ruifrok WP, van Gilst WH, de Boer RA, Sillje HH (2012) Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. Physiol Genomics 44: 443-454
30. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R (2005) Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112: 2339-2346
31. Mitro N, Vargas L, Romeo R, Koder A, Saez E (2007) T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 581: 1721-1726
32. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JA, Lopez-Ilasaca M et al (2005) Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 115: 1913-1922
33. Morin S, Charron F, Robitaille L, Nemer M (2000) GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J 19: 2046-2055
34. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113: 90-97
35. Neubauer S (2007) The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151
36. Ngoh GA, Facundo HT, Zafir A, Jones SP (2010) O-GlcNAc signaling in the cardiovascular system. Circ Res 107: 171-185
37. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328
38. Oberkofler H, Schraml E, Krempler F, Patsch W (2003) Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha. Biochem J 371: 89-96
39. Opie LH, Knuuti J (2009) The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 54: 1637-1646
40. Peet DJ, Janowski BA, Mangelsdorf DJ (1998) The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev 8: 571-575
41. Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA, Misek DE, Kuick R, Hanash SM, Atkins KB et al (2002) Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 22: 5989-5999
42. Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK, Angelin B, Gustafsson JA (2002) Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106: 1147-1153
43. Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129
44. Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, Eguchi J, Sato-Horiguchi C, Uchida HA, Shikata K et al (2012) Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 23: 1835-1846
45. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M et al (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97: 4239-4244
46. Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17: 985-993
47. Ventura-Clapier R, Garnier A, Veksler V, Joubert F (2011) Bioenergetics of the failing heart. Biochim Biophys Acta 1813: 1360-1372
48. Voelkl J, Lin Y, Alesutan I, Ahmed MS, Pasham V, Mia S, Gu S, Feger M, Saxena A, Metzler B et al (2012) Sgk1 sensitivity of Na(+)/H(+) exchanger activity and cardiac remodeling following pressure overload. Basic Res Cardiol 107: 236
49. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopaschuk GD, Allard MF (1999) Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. J Mol Cell Cardiol 31: 493-502
50. Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, Dai M, John SW, Chen YF (2003) Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 42: 88-95
51. Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, Long BW, Prabhu SD, Xuan YT, Jones SP (2010) O-linked beta-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci USA 107: 17797-17802
52. Witteles RM, Fowler MB (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51: 93-102
53. Wu S, Yin R, Ernest R, Li Y, Zhelyabovska O, Luo J, Yang Y, Yang Q (2009) Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 84: 119-126
54. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA et al (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6: 107-117
55. Zelcer N, Tontonoz P (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614
56. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG (2012) Liver LXRalpha expression is crucial for whole body cholesterol homeostasisand reverse cholesterol transport in mice. J Clin Invest 122: 1688-1699